Incyte (INCY) Net Cash Flow Growth (1y) (2011 - 2026)
Incyte (INCY) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Incyte |
19.62 Bn |
15.60 Bn |
1.17 Bn |
43.81% |
| Date | Value |
|---|
| Mar 31, 2026 |
43.81% |
| Dec 31, 2025 |
69.31% |
| Sep 30, 2025 |
57.58% |
| Jun 30, 2025 |
100.62% |
| Mar 31, 2025 |
90.93% |
| Dec 31, 2024 |
6,016.68% |
| Sep 30, 2024 |
239.22% |
| Jun 30, 2024 |
-856.15% |
| Mar 31, 2024 |
202.41% |
| Dec 31, 2023 |
-102.47% |
| Sep 30, 2023 |
-63.18% |
| Jun 30, 2023 |
75.68% |
| Mar 31, 2023 |
-165.37% |
| Dec 31, 2022 |
346.36% |
| Sep 30, 2022 |
24.96% |
| Jun 30, 2022 |
39.30% |
| Mar 31, 2022 |
25.07% |
| Dec 31, 2021 |
254.18% |
| Sep 30, 2021 |
20.41% |
| Jun 30, 2021 |
-54.88% |
